ADDEX THERAPEUTICS INITIATES PIVOTAL PHASE 2B/3 STUDY WITH DIPRAGLURANT FOR DYSKINESIA ASSOCIATED WITH PARKINSON’S DISEASE Geneva, Switzerland, June 29, 2021 – Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering...
Sierra Oncology Announces Completion of Enrollment for MOMENTUM Phase 3 Trial—Topline data anticipated in Q1 2022 with NDA filing to follow in H2 2022— SAN MATEO, Calif., June 21, 2021 /CNW/ – Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical...
Braeburn Resubmits New Drug Application for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder Plymouth Meeting, Pa. – June 15, 2021 – Braeburn announces that today the New Drug Application (NDA) for BRIXADI...
Aptinyx Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder Finalizes design for Phase 2b program, which remains on track to commence in 4Q 2021 Corrects statistical analysis from previous exploratory Phase 2 study—no...
Neurana Pharmaceuticals Announces 50% Enrollment in Phase 3, RESUME-1 Study SAN DIEGO, Calif., June 7, 2021 — Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that 500 of its target 1,000...
Recent Comments